Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure

NCT01802593 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-12-22

No results posted yet for this study

Summary

The goal of the present study is to evaluate the best regimen for infliximab monotherapy, and to evaluate if limited combination therapy with IFX and an Immunomodulator for the first 6 months of therapy, in prior Immunomodulator failures, is superior to monotherapy with Immunomodulator cessation from the second infusion, in preventing loss of remission to IFX.

Conditions

Interventions

DRUG

AZATHIOPRINE or METHOTREXATE

Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks

DRUG

AZATHIOPRINE or METHOTREXATE

Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2) Thiopurine therapy 2 weeks

Sponsors & Collaborators

  • Prof. Arie Levine

    lead OTHER_GOV

Principal Investigators

  • Arie Levine, MD · Pediatric Gastroenterology and Nutrition Unit, The E. Wolfson MC, Tel-Aviv University, Holon, Israel

  • Dan Turner, MD, PhD · Pediatric Gastroenterology and Nutrition Unit, The Hebrew University of Jerusalem, Shaare Zedek MC, Jerusalem, Israel

  • Raanan Shamir, MD · Schneider Childrens Hospital

  • Michal Kori, MD · Kaplan Medical Center

  • Michael Wilshanski, MD · Hadassah Medical Organization

  • Ron Shaoul, MD · Meyer Childrens Hospital Rambam, Haifa, Israel

  • Shlomi Cohen, MD · Tel Aviv Medical Center

  • Batia Weiss, MD · Sheba Medical Center

  • Sarit Peleg, MD · Afula Hospital

  • Baruch Yerushalmi, MD · Soroka University Medical Center

  • Efrat Broide, MD · Asaf Harofe Medical Center

  • Avi On, MD · Poriah Hospital

  • Hussein Chemali, MD · Nazheret Hospital

  • Aharon Lerner, MD · Carmel Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802593 on ClinicalTrials.gov